Pathway Investment

Pathway Investment is a South Korean venture capital firm that specializes in identifying and supporting high-potential technology companies, with a strong focus on the biotechnology and healthcare sectors. Founded in 2021 and led by CEO Lee Sang-jin, the former CFO of medical AI leader VUNO, the firm leverages its leadership’s deep financial and industry expertise to identify and scale innovative startups. Pathway Investment is particularly active in the medical AI and AI-driven drug discovery space, as evidenced by its recent strategic investments in companies such as VUNO and Galux. The firm’s portfolio also includes other prominent biotech and tech innovators like GenEdit, Proteina, and LivsMed. Pathway Investment provides both capital and strategic guidance to its portfolio companies, aiming to foster long-term value and accelerate their global market expansion.